What is OABI's market cap?

$704.51M, based on the Nov 5 close of $4.83.

Does OmniAb pay a dividend?

No regular cash dividend has been paid in the last year.

How much of OABI is sold short?

8.5M shares, 9.7% of float, as of Oct 15, 2026.

What sector is OABI in?

Technology, in the R&D — Physical & Biological Sciences industry.

NASDAQ · OABITechnologyR&D — Physical & Biological Sciences

OmniAb, Inc. Common Stock (OABI)

$4.83−6.76%

Close Nov 5, 2026 · split-adjusted

Nov 5, 2026$4.86▲ 241.05% in range

Nov 5, 2025Low $1.36 · High $5.28Nov 5, 2026

What changed · written from our data

As of Nov 5, 2026

OmniAb closed at $4.83 on Nov 5, down 6.76%, 8.5% below its 52-week closing high. Volume of 1.2M shares was 0.90× its 20-day average (close to normal).

Split-adjusted performance: +5.9% over one month, +228.6% over six months, +226.4% over one year.

In the quarter ended Sep 30, 2026, revenue was $3.99M, up 78.3% from a year earlier, with a net margin of -393.9%.

Short interest was 8.5M shares at the Oct 15 settlement, up 4.2% from the prior report (9.7% of float, 6.7 days to cover).

Market cap$704.5M145.9M shares

Revenue · quarter$4.0M+78.3% YoY

Diluted EPS$-0.12—

P/E · TTM—P/S 17.5×

Net margin-393.9%Gross 92.3%

Dividend yieldNone

52-week range1.36 – 5.28−8.5% from high

Volume1.2M0.90× 20-day avg

Volatility · 60d73.3%Annualised

Short % of float9.7%6.7 days to cover

Net cash$64.2MCash $64.2M

Next earnings—Not scheduled

Split-adjusted performance

1W −7.6%1M +5.9%3M +56.8%6M +228.6%YTD +161.1%1Y +226.4%3Y +6.2%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within R&D — Physical & Biological Sciences

Percentile among 11 companies (100 = best)

6-month momentum100

Revenue growth90

Net margin30

Value (low P/E)—

Size50

Industry medians: 6-month return +48.1%, revenue growth +8.5%, net margin −122.0%, P/E 47.0×.

Short interest

Details →

Shares short8.5M+4.2% vs prior

Days to cover6.7Settled Oct 15

% of float9.7%

Short vol. 10d55.0%of daily volume

Closest peers by size in R&D — Physical & Biological Sciences

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
OABIOmniAb	$4.83	−6.76%	+228.6%	+78.3%	−393.9%	—	$704.5M
NRCNRC Health	$25.48	−5.87%	+36.0%	+11.0%	12.3%	88.2	$540.7M	Compare
ABSIAbsci	$9.39	−10.40%	+63.3%	−46.4%	−10443.4%	—	$1.61B	Compare
MXCTMaxCyte	$1.31	−5.76%	+50.3%	−14.5%	−122.0%	—	$135.2M	Compare
IBACIB Acquisition	$10.81	−0.46%	−0.2%	—	—	—	$54.1M	Compare
CRLCharles River Laboratories International	$313.02	−4.07%	+72.3%	−2.7%	−0.1%	—	$15.00B	Compare
MEDPMedpace Holdings	$634.98	−3.32%	+48.1%	+8.5%	19.2%	34.3	$17.76B	Compare
ONMDOneMedNet	$4.17	−8.15%	−57.3%	+88.4%	−743.8%	—	$24.3M	Compare
INCYIncyte Genomics	$118.01	−3.94%	+20.7%	+14.0%	−50.4%	59.6	$24.05B	Compare

News about OmniAb

All news →

OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research · 6d agoNeutral All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to BuyZacks Investment Research · Oct 6, 2026▲ Positive

Quick answers

What does OmniAb do?: OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts.
What is OABI's market cap?: $704.51M, based on the Nov 5 close of $4.83.
Does OmniAb pay a dividend?: No regular cash dividend has been paid in the last year.
How much of OABI is sold short?: 8.5M shares, 9.7% of float, as of Oct 15, 2026.
What sector is OABI in?: Technology, in the R&D — Physical & Biological Sciences industry.

About OmniAb

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

HQ: Emeryville, CA89 employeesListed Nov 1, 2022omniab.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology